KIO-301 / Kiora Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
KIO-301 / Kiora Pharma
ABACUS, NCT05282953: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia

Recruiting
1/2
12
RoW
KIO-301
Kiora Pharmaceuticals, Inc.
Retinitis Pigmentosa, Choroideremia
12/24
01/25

Download Options